Asia Pacific
Chronic kidney disease (CKD) is a growing global health crisis affecting more than 850 million people worldwide, with an approximate four million people living on dialysis.1,2 And in intensive care units (ICUs) around the world, millions of patients each year experience acute failure of one or more vital organs—including the kidneys and lungs—often as a result of sepsis, trauma, or chronic disease.3,4
These sobering statistics underscore a critical truth: the launch of a new medical product is not the finish line—it’s the starting point of a deeper journey into understanding, improving, and evolving care.
At Vantive, our mission to extend lives and expand possibilities is rooted in a commitment to continuous learning. Rigorous clinical studies are at the heart of our approach. They ensure we bring the right devices to market, that clinical teams adopt them—and, just as importantly, that we continually improve upon them.
For example, in the decade since the introduction of our Sharesource connectivity platform, it has become the most evidenced remote monitoring system for peritoneal dialysis (PD) patients available globally.5
Investing in Improved Outcomes
Every patient interaction—whether in dialysis clinics, ICUs, or home care settings—offers insights that help us refine treatments, identify unmet needs, and anticipate the next wave of innovation. Building on these invaluable learnings, we have committed over $1 billion to innovation across R&D and manufacturing over the next five years.6 We are investing in real-time connectivity, personalized care systems, and evidence generation, as we work to reshape a sustainable system that enables therapy adoption for current and future patients.
Our goal remains clear: to improve patient access, experiences, and outcomes – ensuring vital organ support receives the urgent attention it deserves.
Recent Studies Exemplify Our Commitment to Advancing Outcomes
Several recent publications sponsored by Vantive share a common thread: they represent evidence-based solutions to clinical practice challenges. Through research designed to support improvements in clinical outcomes, quality of life and complemented by ongoing scientific exchange and continuing education, we create a collaborative ecosystem where progress can happen.
Expanding the Critical Care Toolkit
Leveraging three decades of ICU innovation, our acute therapy platforms help critical care and enable personalized treatments. A consensus review in Frontiers in Medicine helps us address guideline gaps for extracorporeal CO₂ removal (ECCO₂R) to allow gentler lung ventilation in patients with acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and asthma.7
Recognizing this challenge, medical experts used a Delphi process driven approach to comprehensively review published clinical studies, real-world evidence and clinical knowledge to enhance clinical understanding of how to use ECCO₂R across various clinical scenarios.7
Boosting Patient-Provider Engagement at Home
Another recent six-month randomized trial published in Peritoneal Dialysis International found that using the MyPD Patient Mobile App enabled three times greater communication between PD patients and their healthcare teams than those receiving care without the app.8 The MyPD app securely collects home patient therapy data and transmits it to the Sharesource Connectivity Platform, Vantive’s two-way remote monitoring platform. This allows healthcare providers to monitor, review, and adjust treatments remotely.8
Our Sharesource platform has powered more than 100 million home dialysis treatments globally, demonstrating improved patient survival, reduced hospitalizations, and greater therapy adherence.9 The MyPD Patient Mobile App allows both continuous ambulatory PD (CAPD) and automated PD (APD) patients to connect to Sharesource.8
HDx Therapy Helps Reduce Mortality
A recent cohort published in Blood Purification, showed an association of approximately 21% reduction in mortality risk for dialysis patients on HDx therapy enabled by the Theranova dialyzer compared to conventional high-flux hemodialysis. The four-year observational study involved over 1,000 Colombian hemodialysis patients.10
What drives the reduction in risk is that HDx therapy utilizes a medium cutoff membrane that efficiently removes large-middle molecules, allowing for filtration closer to that of the natural kidney.11-17 These large-middle molecules have been linked to inflammation, cardiovascular disease, and other comorbidities in dialysis patients.11-13,17
These results provide valuable real-world clinical evidence and adds to evidence indicating HDx therapy may help reduce healthcare resource utilization.10,18-23
For safe and proper use of the devices mentioned herein, please refer to User’s Manual.
Vantive, Sharesource, MyPD, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.